Obesity market news — October 27, 2026
The most useful thing we can tell you this week is the difference between what a company says and what the trial registry says, because two of the field's tracked commitments now sit in exactly that gap. On October 14 Viking Therapeutics announced the initiation of the SUNRISE Phase 3 programme for oral VK2735. Read the release carefully and it does not say dosing has begun, that a first patient was enrolled, or that recruitment has opened; it says the programme has been initiated. The registry is more specific. As of its October 16 update, NCT07868835 and NCT07868939, the two SUNRISE trials, both carry the status NOT YET RECRUITING with an estimated start date of November 2026 and estimated enrolment of 560 each. Both were first posted on October 9. The same pattern sits on the other side of the field: the Phase 2 ZYNERGY trial of petrelintide with Roche's enicepatide, NCT07589686, is registered to Hoffmann-La Roche with an estimated start of September 30, 2026, a status of NOT YET RECRUITING, and a last registry update of September 9. That estimated start date has passed without the record changing. None of this is wrongdoing, and neither company has claimed more than it wrote. Initiating a programme is a real corporate act: protocols are final, sites are contracted, regulators have signed off. It is simply not the same event as a patient taking the first dose, and the gap between the two is where a quarter can disappear. We record both, from both sources, and when they diverge we say so.
The second thing worth reading carefully is the advertising ruling, because the headline and the decision are not the same document. On October 26 Judge Zahid Quraishi, in the federal district court in Trenton, New Jersey, denied Novo Nordisk's request for a preliminary injunction against Eli Lilly's advertising. Novo had argued that ads comparing higher doses of Zepbound and Mounjaro against lower doses of Wegovy and Ozempic were false and misleading. The judge found Novo's showing less than persuasive and said it had failed to establish irreparable harm, noting that money damages could compensate any non-trivial harm and that Lilly's ads appeared to have at most a negligible effect between April and July, with Novo's prescriptions remaining stable. What the ruling did not do is decide whether the advertising is false. The judge said so, the record he relied on was explicitly preliminary, and the case continues. Novo made the same point in its response. For an investor this matters in two directions. The near-term read is simple: Lilly keeps running the campaign while the litigation proceeds, which is a commercial advantage measured in quarters. The longer read is that a court has now looked at Novo's own prescription data and described the ads' effect as negligible. That is an unhelpful fact for the party that brought the case, and it is in the public record regardless of how the merits end.
Viking Therapeutics (VKTX): What changed: Viking announced the initiation of the SUNRISE Phase 3 programme for oral VK2735 on October 14. SUNRISE-1 enrols adults with obesity, or overweight with at least one weight-related comorbidity, without type 2 diabetes; SUNRISE-2 enrols adults with type 2 diabetes who are obese or overweight. Each targets 560 participants on once-daily oral VK2735 at 27.5 mg, 35 mg, 55 mg or placebo for 68 weeks, with percent change in body weight as the primary endpoint. Against what: this was the company's fourth-quarter commitment, carried on our watchlist since September 22, and it is met in the sense the company stated it. What the registry says: NCT07868835 and NCT07868939 were first posted October 9 and, at the October 16 update, both show status NOT YET RECRUITING with an estimated start of November 2026. The release does not claim dosing has begun. We record the commitment as met at the programme level and open at the enrolment level, and we will note the registry status change when it comes.
Novo Nordisk (NVO), Eli Lilly (LLY): What changed: a federal judge denied Novo Nordisk's request for a preliminary injunction to halt Eli Lilly's weight-loss advertising. Judge Zahid Quraishi, sitting in Trenton, New Jersey, ruled following a two-day hearing in late August. Against what: Novo filed the challenge arguing that Lilly's ads compared higher doses of Zepbound and Mounjaro against lower doses of Wegovy and Ozempic. The judge found that Novo had not established irreparable harm, that money damages could compensate any non-trivial harm, and that the ads appeared to have at most a negligible effect between April and July while Novo's prescriptions remained stable. He did not rule on whether the advertising is false, relied on what he called a very preliminary record, and the litigation continues. Lilly said it was pleased with the decision and has denied wrongdoing; Novo said the ruling did not decide the merits.
Zealand Pharma (ZEAL), Roche: What changed: Zealand Pharma reported positive Phase 2 ZUPREME-2 topline results for petrelintide in people with overweight or obesity and type 2 diabetes. The trial enrolled 220 participants in the United States on metformin with or without an SGLT2 inhibitor, with mean baseline body mass index of 36.3 and mean baseline HbA1c of 8.0 percent. At week 28, mean body-weight reduction reached up to 9.2 percent against 2.0 percent on placebo, with a range of 7.4 to 9.2 percent across arms on the efficacy estimand. HbA1c fell by up to 0.65 percent against a 0.23 percent rise on placebo, a placebo-adjusted reduction of 0.61 to 0.88 percent. Discontinuation due to gastrointestinal adverse events was 1.9 percent on petrelintide against 1.7 percent on placebo. These are topline results; the full dataset has not been presented. This landed on the day our last edition went out and we did not carry it.
Eli Lilly (LLY): What changed: the European Medicines Agency's human medicines committee adopted a positive opinion recommending EU approval of orforglipron, sold in the United States as Foundayo, for weight management and for type 2 diabetes in adults. The opinion was adopted on October 15 and announced on October 16. The weight-management recommendation rests on two studies in more than 4,740 adults with obesity or overweight, in which participants lost around 5 to 11 percent of body weight depending on dose against around 2 to 2.5 percent on placebo. The European Commission makes the binding decision, usually within weeks, after which individual member states negotiate price and reimbursement. Orforglipron was approved by the FDA for weight management in April 2026. This is the first oral small-molecule GLP-1 to clear the EU committee stage.
Corxel Pharmaceuticals, Amanat Acquisition Corp: What changed: Corxel Pharmaceuticals entered a definitive business combination agreement with Amanat Acquisition Corp, a special-purpose acquisition company listed on Nasdaq, to take Corxel's US obesity business public. Estimated gross proceeds are about 377 million dollars before transaction costs and assuming no redemptions, comprising roughly 75 million from the SPAC trust and about 300 million from a private placement whose investors include RTW Investments, New Enterprise Associates, SR One and RA Capital Management. Closing is expected in the first half of 2027, subject to shareholder approval. The lead asset is CX11, a once-daily oral small-molecule GLP-1 receptor agonist that reached a mean body-weight reduction of up to 11.5 percent at week 36 in a US Phase 2 trial; the company says it has completed an end-of-Phase-2 meeting with the FDA. A preclinical amylin candidate, CX12, is also included. Proceeds are expected to fund operations through 2029. One caution: coverage differs on whether CX11 has completed Phase 3 testing in Asia, and we could not confirm that from a company filing.
Roche, Zealand Pharma (ZEAL), Viking Therapeutics (VKTX): The watchlist, read from the registry rather than from releases. ZYNERGY, the Phase 2 dose-finding trial of petrelintide with enicepatide, is registered as NCT07589686 to Hoffmann-La Roche, status NOT YET RECRUITING, estimated start September 30, 2026, estimated enrolment 486, first posted May 15 and last updated September 9. The estimated start date has now passed by four weeks without a registry update, while the companies' guidance remains a second-half 2026 initiation. The two SUNRISE trials carry the same status with a November 2026 estimated start. Running total since we began counting on August 31: six tracked commitments, three closed on the record, two open with the registry showing not-yet-recruiting, and one recorded in error and corrected on September 14. We are not asserting delay in either case. We are recording that for three of these trials the public registry and the public announcement currently describe different stages.
ObesityIntel: A note on our own gap. This edition covers three weeks rather than one. The editions due around October 12, October 19 and October 26 did not appear, and the last blog post was published on September 22. The reason is ordinary: the author was travelling for two weeks and we do not publish without his review, because his name is on every edition. We are not backfilling with dated editions that were never written, and nothing below has been given a publication date it did not have. The alternating rhythm this publication adopted on August 28 was designed to absorb a missed week; three is more than it was designed for, and we are saying so rather than letting the archive imply otherwise.
Amgen (AMGN), Altimmune (ALT), Structure Therapeutics (GPCR): We checked for dated corporate announcements from the other followed companies across October 7 to 27 and found none we could confirm from a company source at Amgen, Altimmune or Structure Therapeutics in that window. Amgen's MariTide remains in the Phase 3 MARITIME programme with the primary readout guided to early 2027. This is a checked absence rather than an assumption, and it is a weaker check than usual because three weeks is a long window to sweep. Disclosure: the author holds shares in Novo Nordisk and Eli Lilly, both named in this edition; the full statement is on the About page.